Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update|
|Citation:||Journal of Medicinal Chemistry, 2019; 62(9):4233-4251|
|Publisher:||American Chemical Society|
|Solomon Tadesse, Elizabeth C. Caldon, Wayne Tilley and Shudong Wang|
|Abstract:||Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S- and M-phases of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is critically associated with tumor growth in multiple cancer types. Although the role of CDK2 in tumorigenesis has been controversial, emerging evidence proposes that selective CDK2 inhibition may provide a therapeutic benefit against certain tumors, and it continues to appeal as a strategy to exploit in anticancer drug development. Several small-molecule CDK2 inhibitors have progressed to the clinical trials. However, a CDK2-selective inhibitor is yet to be discovered. Here, we discuss the latest understandings of the role of CDK2 in normal and cancer cells, review the core pharmacophores used to target CDK2, and outline strategies for the rational design of CDK2 inhibitors. We attempt to provide an outlook on how CDK2-selective inhibitors may open new avenues for cancer therapy.|
Protein Kinase Inhibitors
Cyclin-Dependent Kinase 2
Clinical Trials as Topic
|Rights:||© 2018 American Chemical Society|
|Appears in Collections:||Aurora harvest 8|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.